Online citations, reference lists, and bibliographies.
← Back to Search

Study Of The Solid State Of Carbamazepine After Processing With Gas Anti-solvent Technique.

M. Moneghini, I. Kikic, D. Voinovich, B. Perissutti, P. Alessi, A. Cortesi, F. Princivalle, D. Solinas
Published 2003 · Chemistry, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
The purpose of this study was to investigate the influence of supercritical CO2 processing on the physico-chemical properties of carbamazepine, a poorly soluble drug. The gas anti-solvent (GAS) technique was used to precipitate the drug from three different solvents (acetone, ethylacetate and dichloromethane) to study how they would affect the final product. The samples were analysed before and after treatment by scanning electron microscopy analysis and laser granulometry for possible changes in the habitus of the crystals. In addition, the solid state of the samples was studied by means of X-ray powder diffraction, differential scanning calorimetry, diffuse reflectance Fourier-transform infrared spectroscopy and hot stage microscopy. Finally, the in vitro dissolution tests were carried out. The solid state analysis of both samples untreated and treated with CO2, showed that the applied method caused a transition from the starting form III to the form I as well as determined a dramatic change of crystal morphology, resulting in needle-shaped crystals, regardless of the chosen solvent. In order to identify which process was responsible for the above results, carbamazepine was further precipitated from the same three solvents by traditional evaporation method (RV-samples). On the basis of this cross-testing, the solvents were found to be responsible for the reorganisation into a different polymorphic form, and the potential of the GAS process to produce micronic needle shaped particles, with an enhanced dissolution rate compared to the RV-carbamazepine, was ascertained.
This paper references
10.1021/IE00038A051
Solubility and Micronization of Griseofulvin in Supercritical Chf3
E. Reverchon (1995)
10.1023/A:1015970218980
Determination of the Relative Amounts of Anhydrous Carbamazepine (C15H12N2O) and Carbamazepine Dihydrate (C15H12N2O · 2H2O) in a Mixture by Powder X-ray Diffractometry
R. Suryanarayanan (2004)
10.1021/JE960103Q
Solubility of Anti-Inflammatory Drugs in Supercritical Carbon Dioxide
S. J. Macnaughton (1996)
10.1016/S0378-5173(01)00711-6
Processing of carbamazepine-PEG 4000 solid dispersions with supercritical carbon dioxide: preparation, characterisation, and in vitro dissolution.
M. Moneghini (2001)
10.1016/S0378-5173(99)00315-4
Physicochemical properties and bioavailability of carbamazepine polymorphs and dihydrate.
Y. Kobayashi (2000)
10.1016/S0896-8446(01)00064-X
Particle design using supercritical fluids: Literature and patent survey
Jennifer Jung (2001)
10.1002/AIC.690460913
Generation of microparticles using CO2 and CO2‐philic antisolvents
M. Sarkari (2000)
10.1081/PDT-120005725
Action of Carriers on Carbamazepine Dissolution
M. Moneghini (2002)
SEMIQUANTITATIVE IR SPECTROSCOPY OF THE CRYSTAL POLYMORPHS OF CARBAMAZEPINE - A SPECIAL CASE IN THE PH. EUR. AND USP
L. Borka (1992)
Relations between several polymorphic forms and the dihydrate of carbamazepine.
F. U. Krahn (1987)
10.1002/JPS.1065
Crystallization of pure anhydrous polymorphs of carbamazepine by solution enhanced dispersion with supercritical fluids (SEDS).
A. D. Edwards (2001)
A swellable polymer as carbamazepine dissolution rate enhancer.
P. Giunchedi (1990)
10.1021/JS9700661
Pharmaceutical processing with supercritical carbon dioxide.
B. Subramaniam (1997)
10.1002/JPS.10186
Physicochemical characterization of solid dispersions of carbamazepine formulated by supercritical carbon dioxide and conventional solvent evaporation method.
S. Sethia (2002)
10.1016/S0928-0987(01)00115-4
Solubility and conversion of carbamazepine polymorphs in supercritical carbon dioxide.
R. Bettini (2001)
10.1002/JPS.2600760914
Physicochemical properties and X-ray structural studies of the trigonal polymorph of carbamazepine.
M. J. Lowes (1987)
10.1021/JS960338K
X-ray characterization of the triclinic polymorph of carbamazepine.
R. Céolin (1997)
10.1016/0896-8446(95)90033-0
Volume expansions and vapor-liquid equilibria of binary mixtures of a variety of polar solvents and certain near-critical solvents
A. Kordikowski (1995)
10.1021/BK-1989-0406.CH022
Gas Antisolvent Recrystallization: New Process To Recrystallize Compounds Insoluble in Supercritical Fluids
P. Gallagher (1989)
10.1002/cpt1975176657
Pharmacokinetics of carbamazepine in normal man
R. Levy (1975)
10.1016/S0731-7085(00)00262-4
Solid-state study of polymorphic drugs: carbamazepine.
C. Rustichelli (2000)
10.1016/S0896-8446(98)00129-6
SUPERCRITICAL ANTISOLVENT PRECIPITATION OF MICRO- AND NANO-PARTICLES
E. Reverchon (1999)



This paper is referenced by
10.1211/jpp.58.10.0004
Fast‐dissolving microparticles fail to show improved oral bioavailability
S. Wong (2006)
10.1039/C5CE00753D
Influence of isomerism on recrystallization and cocrystallization induced by CO2 as an antisolvent
C. Harscoat-Schiavo (2015)
Micronization of Pharmaceuticals and Food Ingredients using Supercritical Fluid Techniques
R. Adami (2007)
10.1016/J.IJPHARM.2006.03.001
Enhancement of the dissolution rate and oral absorption of a poorly water soluble drug by formation of surfactant-containing microparticles.
S. Wong (2006)
10.3390/pharmaceutics11120629
Using Supercritical Fluid Technology as a Green Alternative During the Preparation of Drug Delivery Systems
Paroma Chakravarty (2019)
10.1016/J.SUPFLU.2013.07.008
Naproxen–nicotinamide cocrystals produced by CO2 antisolvent
C. Neurohr (2013)
10.1080/00218460701587937
Influence of Work of Adhesion on Dissolution Rate in Binary Solid Systems
P. R. Nassab (2007)
10.1007/978-4-431-55555-1_14
Polymorphism in Molecular Crystals and Cocrystals
S. Aitipamula (2015)
10.1016/J.SUPFLU.2011.03.002
Effect of CO2-antisolvent techniques on size distribution and crystal lattice of theophylline
C. Roy (2011)
10.1016/J.JCRYSGRO.2007.09.010
Solvent effect on tolbutamide crystallization induced by compressed CO2 as antisolvent
P. Subra-Paternault (2007)
Effect of Different Stabilizers and Polymers on Spherical Agglomerates of Gresiofulvine by Emulsion Solvent
V. B. Yadav (2009)
10.1016/J.ADDR.2007.03.025
Particle design of poorly water-soluble drug substances using supercritical fluid technologies.
Takehiko Yasuji (2008)
10.1208/s12249-014-0269-6
Stability-enhanced Hot-melt Extruded Amorphous Solid Dispersions via Combinations of Soluplus® and HPMCAS-HF
S. Alshahrani (2014)
10.1016/J.COSSMS.2003.12.005
Fine particle formation using supercritical fluids
Y. Hakuta (2003)
Solubility Enhancement of poorly Water Soluble Drug by Spherical Crystallization Technique
H. Rana (2017)
10.1016/J.SUPFLU.2012.04.010
Micronisation of carbamazepine through rapid expansion of supercritical solution (RESS)
Dennis Bolten (2012)
10.1016/J.SUPFLU.2010.06.013
Piroxicam solid state studies after processing with SAS technique
N. D. Zordi (2010)
10.1016/J.SUPFLU.2006.07.012
A new system for particle formation using the principle of the SAS process: The Concentric Tube Antisolvent Reactor (CTAR)
O. Boutin (2007)
10.1007/s11095-007-9418-x
Comparative Physicochemical Characterization of Phospholipids Complex of Puerarin Formulated by Conventional and Supercritical Methods
Y. Li (2007)
10.1016/J.SUPFLU.2018.02.004
Polymorphism in the co-crystallization of the anticonvulsant drug carbamazepine and saccharin using supercritical CO2 as an anti-solvent
Isaac A. Cuadra (2018)
10.1016/J.ADDR.2007.08.030
Supercritical fluid technologies: an innovative approach for manipulating the solid-state of pharmaceuticals.
I. Pasquali (2008)
10.1016/J.IJPHARM.2006.08.005
Recrystallization of fluconazole using the supercritical antisolvent (SAS) process.
H. J. Park (2007)
10.1016/J.COSSMS.2003.11.001
Dense gas anti-solvent processes for pharmaceutical formulation
F. Dehghani (2003)
10.1021/CG900467D
Modeling of Griseofulvin Recrystallization Conducted in a Supercritical Antisolvent Process
O. Boutin (2009)
10.1208/s12249-008-9130-0
Self-built Supercritical CO2 Anti-solvent Unit Design, Construction and Operation using Carbamazepine
D. Meng (2008)
Review of role of physical properties of crystals in dosage forms performance
M. Maryam (2008)
10.1016/J.AJPS.2015.12.001
Effect of process parameters on the recrystallization and size control of puerarin using the supercritical fluid antisolvent process
Y. Li (2016)
Semantic Scholar Logo Some data provided by SemanticScholar